Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 14, 2026, titled "Zydus new drug discovery, Desidustat licensed to China Medical System Holdings receives approval from NMPA of China".
Press Release Mar 14 2026
Filed with NSE · · 4 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced that its drug Desidustat has received approval from the National Medical Products Administration of China for treating renal anaemia. This approval follows positive results from a Phase III clinical trial conducted in China. The Managing Director of Zydus expressed confidence that this partnership will enhance access to treatment for patients in Greater China.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 13 2026
- Press Release Mar 12 2026
- Press Release Feb 28 2026
- Press Release Feb 27 2026
- Press Release Feb 25 2026
Later from Zydus Lifesciences
- Press Release Mar 16 2026
- Press Release Mar 17 2026
- Press Release Mar 18 2026
- AeroDel signs exclusive licensing arrangement with Zydus for launching Aerolife Mini™, India's First Foldable, 'Always Attached' pMDI Enhancer
- Press Release Mar 19 2026
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences